Teva Pharmaceutical Industries (STU:TEV) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:TEV Teva Pharmaceutical Industries Ltd STU:TEV
50 GF Score
Price €31.60
GF Value €17.91
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Teva Pharmaceutical Industries Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Teva Pharmaceutical Industries's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €3,936 Mil. Teva Pharmaceutical Industries's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €10,823 Mil. Teva Pharmaceutical Industries's annualized EBITDA for the quarter that ended in Jun. 2026 was €172 Mil. Teva Pharmaceutical Industries's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was 85.80.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Teva Pharmaceutical Industries's Debt-to-EBITDA or its related term are showing as below:

STU:TEV' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -23.31   Med: 10.26   Max: 174.19
Current: 6.67

During the past 13 years, the highest Debt-to-EBITDA Ratio of Teva Pharmaceutical Industries was 174.19. The lowest was -23.31. And the median was 10.26.

STU:TEV's Debt-to-EBITDA is ranked worse than
86.87% of 678 companies
in the Drug Manufacturers industry
Industry Median: 1.64 vs STU:TEV: 6.67

Teva Pharmaceutical Industries  (STU:TEV) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Teva Pharmaceutical Industries Debt-to-EBITDA Related Terms

Teva Pharmaceutical Industries Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Teva Pharmaceutical Industries's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Teva Pharmaceutical Industries Debt-to-EBITDA Chart

Teva Pharmaceutical Industries Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Teva Pharmaceutical Industries Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

STU:TEV vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Teva Pharmaceutical Industries Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's Debt-to-EBITDA falls into.


STU:TEV
50GF Score
Teva Pharmaceutical Industries Ltd STU:TEV
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Teva Pharmaceutical Industries Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Teva Pharmaceutical Industries's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1630.5512791989 + 13036.747068311) / 2805.3001952979
=5.23

Teva Pharmaceutical Industries's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3935.9740363368 + 10823.053939029) / 172.01188203852
=85.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Is Teva Pharmaceutical Industries (STU:TEV) Overvalued in 2026?

Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued. The current stock price of €31.60 is trading 76.4% above its estimated GF Value™ of €17.91. GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.

Key valuation signals for STU:TEV:

  • Debt-to-EBITDA:
  • GF Value™: €17.91 vs. price of €31.60 (76.4% above fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the STU:TEV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Teva Pharmaceutical Industries Business Description

Address 124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
50GF Score

Get the complete analysis for STU:TEV

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€31.60
Price
€17.91
GF Value